NCT01845675View on ClinicalTrials.gov

Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

November 30, 2016

Study Completion Date

March 31, 2017

Conditions
Advanced Well-differentiated Pancreatic Neuroendocrine Tumor
Interventions
DRUG

temozolomide or dacarbazine-based chemotherapy, endostatin

Trial Locations (1)

100730

Division of Medical Oncology, Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT01845675 - Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor | Biotech Hunter | Biotech Hunter